Abstract
No public abstract is available from the verified source records.
Silvio E. Inzucchi
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
New perspectives in management of cardiovascular risk among people with diabetes
10.1161/jaha.123.034053 · 2024
Pioglitazone: the forgotten, cost-effective cardioprotective drug for type 2 diabetes
10.1177/1479164118825376 · 2019
Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
10.2337/dci22-0034 · 2022
Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association
10.1161/cir.0000000000001040 · 2022
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes
10.1093/eurheartj/ehad192 · 2023
Cardiovascular and kidney outcomes and mortality with long-acting injectable and oral glucagon-like peptide 1 receptor agonists in individuals with type 2 diabetes: a systematic review and meta-analysis of randomized trials
10.2337/dc24-1533 · 2025
Estimating the true MACE benefits from tirzepatide in SURPASS-CVOT using an imputed placebo analysis of REWIND
10.2337/dc26-0298 · 2026
Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes
10.1056/nejmoa2505928 · 2025
Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
10.1007/s00125-022-05715-4 · 2022
Tirzepatide and cardiometabolic parameters in obesity: summary of current evidence
10.1111/dom.16549 · 2025
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
10.1016/s0140-6736(19)31149-3 · 2019
Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
10.1056/nejmoa1607141 · 2016
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
10.1056/nejmoa2108269 · 2021
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
10.1016/s0140-6736(18)32261-x · 2018
Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial
10.2337/dc19-2251 · 2020
Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial
10.1016/s0140-6736(25)01375-3 · 2025
Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: a meta-analysis of randomized placebo-controlled trials
10.1016/j.ajpc.2024.100679 · 2024
GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes
10.1161/circulationaha.122.059595 · 2022
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
10.1038/s41569-023-00849-3 · 2023
Antiinflammatory actions of glucagon-like peptide-1-based therapies beyond metabolic benefits
10.1172/jci194751 · 2025
Emerging pharmacotherapies for obesity: a systematic review
10.1124/pharmrev.123.001045 · 2025
The glitazars paradox: cardiotoxicity of the metabolically beneficial dual PPARα and PPARγ activation
10.1097/fjc.0000000000000891 · 2020
No additional external references are available.